ArticleCancer2008
Heparanase is overexpressed in lung cancer and correlates inversely with patient survival.
Article in Cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 67 citations in OpenAlex.
- Integrated 3D-QSAR and cellular profiling of sulfated and hydrophobic aminoglycoside glycans to modulate heparanase activity.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Identification of Progression-Associated Biomarkers in Lung Cancer Based on the Integrated Analysis of RNA Sequencing Data From Platelets and Tumor Tissues.International journal of genomics · 2025Article
- Heparanase accelerates the angiogenesis and inhibits the ferroptosis of p53-mutant non-small cell cancers in VEGF-dependent manner.Cytotechnology · 2024Article
- The Role of KRAS Mutation in Colorectal Cancer-Associated Thrombosis.International journal of molecular sciences · 2023Article
- A Universal and Modular Scaffold for Heparanase Activatable Probes and Drugs.Bioconjugate chemistry · 2022Article
- Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma.World journal of surgical oncology · 2022Article
- The Heparanase Regulatory Network in Health and Disease.International journal of molecular sciences · 2021Review
- Review
- Ultrasensitive small molecule fluorogenic probe for human heparanase.Chemical science · 2020Article
- Review
- Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer.Oncotarget · 2018Article
- Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.Frontiers in endocrinology · 2018Review
- Molecular analysis of single circulating tumour cells following long-term storage of clinical samples.Molecular oncology · 2017Article
- Design, synthesis, and evaluation of heparan sulfate mimicking glycopolymers for inhibiting heparanase activity.Chemical communications (Cambridge, England) · 2017Article
- PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Glycosylation alterations in lung and brain cancer.Advances in cancer research · 2015Review
- The close correlation between heparanase and COX-2 expression in lymphangiogenesis of cervical cancer.Medical oncology (Northwood, London, England) · 2014Article
- Article
- Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo.Medical oncology (Northwood, London, England) · 2013Article
- Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway.Cardiovascular diabetology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundHeparanase is an endo-beta-D-glucuronidase that is capable of cleaving heparan sulfate (HS) side chains at a limited number of sites, yielding HS fragments of still appreciable size (approximately 5-7 kDa). Heparanase activity has been detected frequently in several cell types and tissues. Heparanase activity correlates with the metastatic potential of tumor-derived cells, a correlation that has been attributed to enhanced cell dissemination as a consequence of HS cleavage and remodeling of the extracellular matrix barrier.
methodsIn this study, the authors examined heparanase expression in 114 patients with lung cancer by means of immunohistochemistry and correlated clinical-pathologic data with heparanase immunostaining and cellular localization.
resultsHeparanase was overexpressed in 75% of the study patients. Heparanase expression was correlated with lung cancer lymph node status and metastasis classification (P = .04 and P = .01, respectively) and was correlated inversely with patient survival (P = .007). It is noteworthy that this adverse effect depended largely on the cellular localization of heparanase. Thus, whereas cytoplasmic staining of heparanase is associated with a poor prognosis, nuclear heparanase predicts a favorable outcome for patients with lung cancer.
conclusionsThe current findings suggest that heparanase expression and cellular localization are decisive for lung cancer patients' prognosis, most likely because of heparanase-mediated tumor cell dissemination by blood and lymph vessels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.